ThoraGraft™
2 year shelf life
ThoraGraft is aseptically contained within a sealed thermoformed inner tray, outer tray and box.
At the surgeon’s discretion, ThoraGraft™ may be used as a delivery tissue for biologic agents like PRP, bone marrow aspirate, synthetic bone morphogenic protein or other bone forming biologic concentrations.
thoragraft = demineralized FIBROUS bone graft
LENGTH: 100MM ~ WIDTH: 25MM ~ HEIGHT: 6MM
ThoraGraft™ is a processed demineralized bone fibrous graft designed to provide surgeons with a bone allograft suitable for use in place of autograft wherever bone graft tissue is required.
ThoraGraft™ is 100% bone and has osteoconductive and osteoinductive properties.
Based on an analysis of 21 CFR Part 1271, CoreLogix Medical™ and AlloSource® determined that ThoraGraft™ is a Human Cell and Tissue Product. It is an allogeneic demineralized cortical bone fiber matrix intended for homologous use in the repair, replacement or reconstruction of musculoskeletal defects.
Proprietary Technology
Our technology is a proprietary tissue graft implanted between the sternal halves prior to closure in open heart or lung procedures. ThoraGraft™ addresses pain, bleeding, dehiscence and other post-operative complications while promoting healing and sternal fusion to deliver improved patient outcomes, reduced complications and lower healthcare costs.
The fibers in ThoraGraft™ provide an osteoconductive scaffold with osteoinductive potential for bone ingrowth, while providing optimal handling characteristics for implantation.
ThoraGraft™ is aseptically processed, packed and sterilized via a validated electron beam irradiation process.
2 year shelf life at room temperature
ThoraGraft™ is packaged in a pressed, flexible graft configuration for surgical use by licensed physicians/clinicians.
The graft is not to be exposed to extreme heat or frozen.
Resolves significant and costly post-operative sternotomy complications related to thoracic surgeries. Sternotomy complications vary extensively, costing upwards of $450,000 per incident.
*Note: Patent pending technology for use in thoracic procedures.